688166 博瑞醫藥
按盤價 
96.470 -1.570 (-1.601%) | 2025/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 537,439 | -18.28% | 1,282,552 | 1,179,518 | 1,017,331 | 1,052,409 | |
| 減：營業總成本 | 549,542 | -0.84% | 1,102,599 | 980,323 | 783,331 | 789,486 | |
| 其中:營業成本 | 275,666 | -6.24% | 544,951 | 521,414 | 376,299 | 460,671 | |
| 財務費用 | 19,738 | 4.63% | 40,909 | 24,140 | 9,800 | 5,740 | |
| 資產減值損失 | (2,766) | -47.14% | (19,943) | (21,490) | (14,649) | (9,396) | |
| 公允價值變動收益 | 1,586 | -201.40% | (5,700) | (520) | (3,395) | 790 | |
| 投資收益 | (5,428) | -17.56% | (11,634) | (14,741) | 3,957 | 9,231 | |
| 其中：對聯營企業和合營企業的投資收益 | (3,023) | -38.33% | (9,162) | (13,605) | (8,917) | (9,236) | |
| 營業利潤 | (4,822) | -105.11% | 160,289 | 190,244 | 242,155 | 258,991 | |
| 利潤總額 | (5,021) | -105.32% | 157,201 | 188,770 | 242,207 | 257,455 | |
| 減：所得稅費用 | (6,678) | -155.29% | 15,937 | 15,346 | 30,780 | 19,897 | |
| 淨利潤 | 1,657 | -97.98% | 141,263 | 173,424 | 211,427 | 237,558 | |
| 減：非控股權益 | (15,516) | -35.72% | (47,904) | (29,042) | (28,196) | (6,393) | |
| 股東淨利潤 | 17,173 | -83.85% | 189,167 | 202,466 | 239,623 | 243,951 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.040 | -84.00% | 0.450 | 0.480 | 0.580 | 0.600 | |
| 每股派息 (元) * | -- | -- | 0.096 | 0.096 | 0.114 | 0.120 | |
| 每股淨資產 (元) * | 5.704 | 4.23% | 5.489 | 5.428 | 5.009 | 4.093 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 29/08/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
